Physician profile
Daniel A Neumann
NPI 1295719094
$10,709.80
in general payments reported to CMS, 2019-2025
31 companies · $980 in 2025
The $980 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,212 · 2020: $404 · 2021: $2,406 · 2022: $1,004 · 2023: $3,131 · 2024: $1,572 · 2025: $980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,743 · Travel and Lodging: $1,591 · Consulting Fee: $1,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,742.71 |
| Travel and Lodging | $1,590.69 |
| Consulting Fee | $1,350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,885.00 | 2021 | |
| Abbvie INC. | $1,774.25 | 2019-2025 | |
| Exact Sciences Corporation | $1,415.77 | 2023 | Cologuard Collection Kit |
| Medtronic, INC. | $1,152.39 | 2024-2025 | Gi Genius, Interstim |
| Roche Diagnostics Corporation | $716.52 | 2023 | Iscan Coreo, Virtuoso System For Ihc |
| Takeda Pharmaceuticals U.S.A., INC. | $591.74 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $577.71 | 2020-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $531.00 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $503.59 | 2023-2025 | Omvoh |
| Gilead Sciences, INC. | $192.03 | 2019-2022 | |
| Boston Scientific Corporation | $148.45 | 2019 | |
| Echosens North America, INC. | $144.36 | 2023-2024 | Fibroscan |
| Merck Sharp & Dohme LLC | $142.92 | 2019-2023 | Dificid |
| Ardelyx, INC. | $125.25 | 2023-2024 | Ibsrela |
| Janssen Scientific Affairs, LLC | $118.72 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $108.55 | 2019-2023 | Linzess |
| Celgene Corporation | $101.45 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $99.81 | 2019-2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $93.13 | 2021-2023 | |
| Braintree Laboratories, INC. | $81.87 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $51.14 | 2024-2025 | Rebyota |
| Pfizer INC. | $27.99 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $21.71 | 2022 | |
| Shire North American Group INC | $20.86 | 2019 | |
| Daiichi Sankyo INC. | $20.23 | 2019 | |
| Romark Laboratories, Lc | $20.09 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $16.85 | 2022 | |
| Intra-Sana Laboratories | $15.38 | 2022 | |
| Qol Medical, LLC | $11.04 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Neumann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.